Overview

Cerebrolysin REGistry Study in Stroke

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
0
Participant gender:
All
Summary
Investigation of clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with acute ischemic stroke.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ever Neuro Pharma GmbH
Collaborator:
SITS International
Treatments:
Cerebrolysin
Criteria
Inclusion Criteria:

- Signed informed consent

- Clinical diagnosis of acute ischemic stroke

- Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1)

- Reasonable expectation of successful follow-up (max. 100 days)

Exclusion Criteria:

- none